Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Rating of “Buy” by Analysts

Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) have been given an average recommendation of “Buy” by the ten research firms that are presently covering the company, Marketbeat reports. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $9.31.

TRVI has been the topic of a number of recent research reports. Leerink Partners initiated coverage on shares of Trevi Therapeutics in a report on Monday, September 9th. They set an “outperform” rating and a $7.00 price target on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $8.00 target price on shares of Trevi Therapeutics in a report on Thursday, December 12th. Leerink Partnrs upgraded shares of Trevi Therapeutics to a “strong-buy” rating in a report on Monday, September 9th. B. Riley reiterated a “buy” rating and issued a $6.00 target price on shares of Trevi Therapeutics in a report on Monday, October 7th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $21.00 target price on shares of Trevi Therapeutics in a report on Thursday, December 12th.

Trevi Therapeutics Stock Down 5.9 %

Shares of NASDAQ:TRVI opened at $4.32 on Thursday. The firm has a fifty day moving average of $3.31 and a two-hundred day moving average of $3.10. The firm has a market capitalization of $332.06 million, a P/E ratio of -9.82 and a beta of 0.87. Trevi Therapeutics has a 12-month low of $1.27 and a 12-month high of $4.68.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). During the same quarter last year, the company posted ($0.08) EPS. Equities research analysts expect that Trevi Therapeutics will post -0.49 earnings per share for the current fiscal year.

Institutional Trading of Trevi Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of TRVI. Ally Bridge Group NY LLC acquired a new stake in Trevi Therapeutics in the 2nd quarter worth $4,395,000. Logos Global Management LP grew its position in Trevi Therapeutics by 27.3% in the 2nd quarter. Logos Global Management LP now owns 2,800,000 shares of the company’s stock worth $8,344,000 after purchasing an additional 600,000 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in Trevi Therapeutics in the 3rd quarter worth $409,000. Geode Capital Management LLC grew its position in Trevi Therapeutics by 10.2% in the 3rd quarter. Geode Capital Management LLC now owns 1,264,166 shares of the company’s stock worth $4,223,000 after purchasing an additional 117,418 shares during the last quarter. Finally, Fred Alger Management LLC acquired a new stake in Trevi Therapeutics in the 3rd quarter worth $256,000. 95.76% of the stock is currently owned by institutional investors and hedge funds.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.